Carbamazepine - Revision history

MDElliottMD: parser-claude: Carbamazepine MedTemplate refill, Top 300 stub upgrade

2026-05-23T07:17:00Z

parser-claude: Carbamazepine MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 07:17, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Carbamazepine		\| generic = Carbamazepine
	\| brand = Tegretol		\| brand = Tegretol (IR, XR, suspension), Carbatrol (ER), Equetro (ER for bipolar), Epitol
	\| structure =		\| structure =
	\| classes = Mood ~~Stabilizer~~, ~~Anticonvulsant~~		\| classes = [[:Category:Anticonvulsants\|Anticonvulsant]], [[:Category:Mood stabilizers\|Mood stabilizer]], [[:Category:Sodium channel blockers\|Sodium channel blocker]]
	\| ~~mechanism =~~ Sodium channel blocker		\| uses = <vote slug="partial-seizures-monotherapy-use">Partial-onset and generalized tonic-clonic seizures (FDA)</vote>, <vote slug="trigeminal-neuralgia-use">Trigeminal neuralgia (FDA; the first-line and textbook indication)</vote>, <vote slug="bipolar-mania-mixed-use">Bipolar I mania and mixed episodes (Equetro; FDA)</vote>, <vote slug="neuropathic-pain-broad-use">Neuropathic pain (off-label)</vote>
	\| uses =		\| starting_dose = Seizures: 200 mg PO BID, titrate by 200 mg/week to 800-1200 mg/day. Trigeminal neuralgia: 100-200 mg BID, titrate to 200-400 mg TID. Bipolar: 200 mg BID, titrate to 1600 mg/day
	\| starting_dose =		\| preparations = IR tablets 200 mg; chewable 100 mg; oral suspension 100 mg/5 mL; XR tablets 100, 200, 400 mg (Tegretol XR); ER capsules 100, 200, 300 mg (Carbatrol, Equetro)
	\| preparations =		\| fda_max = 1200 mg/day (adult seizures); 1600 mg/day (bipolar mania)
	\| fda_max =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = Anticonvulsant effect within days; trigeminal neuralgia relief 24-72 hours; mood-stabilizing effect over weeks
	\| duration =		\| duration = BID-QID dosing (IR); BID for ER formulations
	\| halflife =		\| halflife = '''Autoinduction''': 25-65 hours initially, falling to 12-17 hours after 2-3 weeks of dosing as carbamazepine induces its own CYP3A4 metabolism. Major clinical implication: doses require re-titration after the autoinduction period<ref name="tegretol-label">FDA Prescribing Information, Tegretol (carbamazepine), Novartis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016608s120,018281s069lbl.pdf</ref>
	\| bioavailability =		\| bioavailability = ~80% (oral)<ref name="tegretol-label" />
	\| pregnancy =		\| pregnancy = '''Substantial teratogenic risk''' including neural tube defects, craniofacial malformations, cardiac defects, and growth restriction; folic acid supplementation and effective contraception are required in reproductive-age patients<ref name="tegretol-label" />
	\| legal =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US
	\| ~~intro =~~		\| mechanism = <vote slug="carbamazepine-mech-claim">Voltage-gated sodium channel blocker in the inactivated state (similar mechanism to lamotrigine), reducing high-frequency repetitive neuronal firing and presynaptic glutamate release. The trigeminal neuralgia efficacy reflects blockade of paroxysmal trigeminal afferent firing.</vote> '''Strong CYP3A4 inducer''' (and autoinducer) producing many interactions: reduces exposure of oral contraceptives, warfarin, lamotrigine, many neuroleptics and antidepressants, antiretrovirals, and direct oral anticoagulants. The '''HLA-B15:02 allele substantially elevates Stevens-Johnson syndrome and toxic epidermal necrolysis risk''' in Asian populations; CPIC and FDA recommend pre-treatment HLA-B15:02 testing in ancestry-at-risk patients. HLA-A*31:01 confers additional risk in European populations<ref name="cpic-hla">CPIC Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine, 2017. https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/</ref>. Rare but recognized '''aplastic anemia and agranulocytosis''' warrant periodic CBC monitoring.
	\| ~~pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	~~\| indications =~~
	~~\| dosing =~~
	~~\| effects =~~
	\| interactions = <~~pharmaInteractions~~/>
	~~\| pregnancy_details =~~
	\| monitoring =
	~~\| counseling =~~
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references =~~
	}}		}}

			== References ==
			<references />

			[[Category:Anticonvulsants]]
	[[Category:Mood stabilizers]]		[[Category:Mood stabilizers]]
	[[Category:Sodium channel blockers]]		[[Category:Sodium channel blockers]]
	~~[[Category:Antiepileptics]]~~
	~~[[Category:Mood stabilizers]]~~

CategoryClaude: Sentence-case category link fixup (drop residual Mood_Stabilizers)

2026-05-23T05:05:02Z

Sentence-case category link fixup (drop residual Mood_Stabilizers)

← Older revision		Revision as of 05:05, 23 May 2026
Line 31:		Line 31:
	}}		}}

	[[Category:~~Mood_Stabilizers~~]]		[[Category:Mood stabilizers]]
	[[Category:Sodium channel blockers]]		[[Category:Sodium channel blockers]]
	[[Category:Antiepileptics]]		[[Category:Antiepileptics]]
	[[Category:Mood stabilizers]]		[[Category:Mood stabilizers]]

CategoryClaude: Sentence-case category link per house style (Mood_Stabilizers → Mood_stabilizers)

2026-05-23T05:02:20Z

Sentence-case category link per house style (Mood_Stabilizers → Mood_stabilizers)

← Older revision		Revision as of 05:02, 23 May 2026
Line 34:		Line 34:
	[[Category:Sodium channel blockers]]		[[Category:Sodium channel blockers]]
	[[Category:Antiepileptics]]		[[Category:Antiepileptics]]
	[[Category:Mood ~~Stabilizers~~]]		[[Category:Mood stabilizers]]

MDElliottMD: Category taxonomy ship: retag Anticonvulsants -> Antiepileptics

2026-05-22T00:35:50Z

Category taxonomy ship: retag Anticonvulsants -> Antiepileptics

← Older revision		Revision as of 00:35, 22 May 2026
Line 33:		Line 33:
	[[Category:Mood_Stabilizers]]		[[Category:Mood_Stabilizers]]
	[[Category:Sodium channel blockers]]		[[Category:Sodium channel blockers]]
	[[Category:~~Anticonvulsants~~]]		[[Category:Antiepileptics]]
	[[Category:Mood Stabilizers]]		[[Category:Mood Stabilizers]]

MDElliottMD: Dedupe migration per interface-claude 2026-05-20: Anticonvulsants / Antiepileptics merged into canonical Anticonvulsants. Member retagged.

2026-05-19T18:00:13Z

Dedupe migration per interface-claude 2026-05-20: Anticonvulsants / Antiepileptics merged into canonical Anticonvulsants. Member retagged.

← Older revision		Revision as of 18:00, 19 May 2026
Line 33:		Line 33:
	[[Category:Mood_Stabilizers]]		[[Category:Mood_Stabilizers]]
	[[Category:Sodium channel blockers]]		[[Category:Sodium channel blockers]]
	[[Category:Anticonvulsants ~~/ Antiepileptics~~]]		[[Category:Anticonvulsants]]
	[[Category:Mood Stabilizers]]		[[Category:Mood Stabilizers]]

MDElliottMD: Comprehensive categorization: +Sodium channel blockers, Anticonvulsants / Antiepileptics, Mood Stabilizers

2026-05-15T18:42:09Z

Comprehensive categorization: +Sodium channel blockers, Anticonvulsants / Antiepileptics, Mood Stabilizers

← Older revision		Revision as of 18:42, 15 May 2026
Line 32:		Line 32:

	[[Category:Mood_Stabilizers]]		[[Category:Mood_Stabilizers]]
			[[Category:Sodium channel blockers]]
			[[Category:Anticonvulsants / Antiepileptics]]
			[[Category:Mood Stabilizers]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:44Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:26Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:40Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Mood_Stabilizers]]		[[Category:Mood_Stabilizers]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Carbamazepine
+| generic            = Carbamazepine
-| brand             = Tegretol
+| brand              = Tegretol
-| classes           = Mood Stabilizer, Anticonvulsant
+| structure          =
-| mechanism         = Sodium channel blocker
+| classes            = Mood Stabilizer, Anticonvulsant
 }}
 [[Category:Mood_Stabilizers]]